Wei Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Xu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jianlan Cui
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
4 shared publications - Xi Li
National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
4 shared publications - Lijuan Song
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
3 shared publications - Yang Yang
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
3 shared publications - Yunfeng Wang
Shenzhen Clinical Research Center for Cardiovascular Diseases, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong, China
3 shared publications - Bowang Chen
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
2 shared publications
Latest Publications
- Open Access
Protein biomarkers for predicting incident carotid plaque: a nested case–control study in the ChinaHEART cohort with transportability assessment in the UK Biobank
Objectives: Carotid plaque is an early manifestation of atherosclerosis and is closely associated with the risk of myocardial ischaemia, ischaemic stroke and other atherosclerotic cardiovascular diseases (ASCVDs). To identify new protein biomarkers associated with carotid plaque, which will enhance early warning of ASCVDs Design: Nested case–control study within a prospective cohort, with external assessment of transportability in an independent population-based cohort. Participants and data sources: The development cohort is from China, which is a nationwide, community-based cohort and the external validation cohort is from the UK Biobank in the UK. In the development cohort, 292 participants without carotid plaque at baseline were included, comprising 145 incident cases and 147 matched controls selected based on age, sex, low-density lipoprotein cholesterol, systolic blood pressure, body mass index, smoking status and diabetes history. In the validation dataset, 30 800 participants without baseline cardiovascular disease were included from a large population-based cohort. Results: A total of 11 biomarkers, including thrombomodulin, intercellular cell adhesion molecule-3, P-selectin, growth differentiation factor-15, adiponectin, monocyte chemoattractant protein-1, IL-10, placental growth factor, tyrosine kinase receptor-2, vascular endothelial growth factor-D and vascular cell adhesion molecule-1, were selected by least absolute shrinkage and selection operator regression and used to construct a prediction model for the carotid plaque. The area under the receiver operator characteristic curve (AUC) of the eventual model is 0.761, and it showed good calibration capability graphically with a Brier score of 0.192. In the UK Biobank cohort, when these biomarkers were added to a traditional predictive model, a better predictive power was generated, with an AUC improvement of 0.021 (p<0.001, Delong test), Brier score of 0.093, a continuous net reclassification improvement of 0.259 (0.223–0.294, p<0.001) and an integrated discrimination improvement of 0.017 (0.015–0.019, p<0.001) relative to the traditional model. Conclusions: The identified protein biomarkers were used to predict carotid plaque and may provide modest incremental value for risk stratification beyond traditional risk factors. However, the findings should be interpreted with caution and further studies are needed to evaluate their clinical utility.
Open AccessProtein biomarkers for predicting incident carotid plaque: a nested case–control study in the ChinaHEART cohort with transportability assessment in the UK Biobank
Objectives: Carotid plaque is an early manifestation of atherosclerosis and is closely associated with the risk of myocardial ischaemia, ischaemic stroke and other atherosclerotic cardiovascular diseases (ASCVDs). To identify new protein biomarkers associated with carotid plaque, which will enhance early warning of ASCVDs Design: Nested case–control study within a prospective cohort, with external assessment of transportability in an independent population-based cohort. Participants and data sources: The development cohort is from China, which is a nationwide, community-based cohort and the external validation cohort is from the UK Biobank in the UK. In the development cohort, 292 participants without carotid plaque at baseline were included, comprising 145 incident cases and 147 matched controls selected based on age, sex, low-density lipoprotein cholesterol, systolic blood pressure, body mass index, smoking status and diabetes history. In the validation dataset, 30 800 participants without baseline cardiovascular disease were included from a large population-based cohort. Results: A total of 11 biomarkers, including thrombomodulin, intercellular cell adhesion molecule-3, P-selectin, growth differentiation factor-15, adiponectin, monocyte chemoattractant protein-1, IL-10, placental growth factor, tyrosine kinase receptor-2, vascular endothelial growth factor-D and vascular cell adhesion molecule-1, were selected by least absolute shrinkage and selection operator regression and used to construct a prediction model for the carotid plaque. The area under the receiver operator characteristic curve (AUC) of the eventual model is 0.761, and it showed good calibration capability graphically with a Brier score of 0.192. In the UK Biobank cohort, when these biomarkers were added to a traditional predictive model, a better predictive power was generated, with an AUC improvement of 0.021 (p<0.001, Delong test), Brier score of 0.093, a continuous net reclassification improvement of 0.259 (0.223–0.294, p<0.001) and an integrated discrimination improvement of 0.017 (0.015–0.019, p<0.001) relative to the traditional model. Conclusions: The identified protein biomarkers were used to predict carotid plaque and may provide modest incremental value for risk stratification beyond traditional risk factors. However, the findings should be interpreted with caution and further studies are needed to evaluate their clinical utility.
- Open Access
Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort
Background Evidence of socioeconomic status (SES)-related health inequality is scarce in patients with cardiovascular diseases (CVDs) who need both lifestyle change and medical care, particularly in developing countries. Methods The study employed a nationwide population-based cohort design, covering all 31 provinces of Chinese mainland from September 2014 to March 2021. Participants aged 35–75 years with self-reported CVD diagnoses were included. Information on SES and lifestyle details were collected via a questionnaire, and the unequal mortality across SES groups and the mediating effects of lifestyles were explored. Results Among the 104 718 participants included, 27 943 (26.7%) were allocated to high SES, 35 802 (34.2%) were allocated to medium SES and 40 973 (39.1%) were allocated to low SES. During a mean follow-up of 48.9±18.9 months, 5010 deaths were recorded. Participants with low SES had a 65% (HR=1.65, 95% CI: 1.50 to 1.80) greater risk of all-cause death and a 95% (HR=1.95, 95% CI: 1.72 to 2.20) greater risk of CVD death in Chinese communities. A low SES with the worst lifestyle was associated with a significant increase in the risk of all-cause mortality by 172% (HR=2.72, 95% CI: 2.37 to 3.12) and CVD mortality by 218% (HR=3.18, 95% CI: 2.64 to 3.83) compared with a high SES with healthy lifestyle. The joint mediating effects of lifestyles on CVD mortality accounted for 19.6% (95%CI: 14.8% to 24.2%) of the excess mortality risk for individuals with low SES, and these effects varied by genders (p for interaction=0.013) and urbanity (p for interaction=0.004). Leisure-time physical activity was the strongest mediator, followed by dietary factors. For all-cause mortality, outcomes were similar to this. Conclusions Both SES-related health inequalities and lifestyle disparities should be comprehensively considered when caring for this population, and upstream structural interventions that integrate SES and lifestyle factors and are tailored to the target population are urgently needed. Trial registration number NCT02536456.
Open AccessCardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort
Background Evidence of socioeconomic status (SES)-related health inequality is scarce in patients with cardiovascular diseases (CVDs) who need both lifestyle change and medical care, particularly in developing countries. Methods The study employed a nationwide population-based cohort design, covering all 31 provinces of Chinese mainland from September 2014 to March 2021. Participants aged 35–75 years with self-reported CVD diagnoses were included. Information on SES and lifestyle details were collected via a questionnaire, and the unequal mortality across SES groups and the mediating effects of lifestyles were explored. Results Among the 104 718 participants included, 27 943 (26.7%) were allocated to high SES, 35 802 (34.2%) were allocated to medium SES and 40 973 (39.1%) were allocated to low SES. During a mean follow-up of 48.9±18.9 months, 5010 deaths were recorded. Participants with low SES had a 65% (HR=1.65, 95% CI: 1.50 to 1.80) greater risk of all-cause death and a 95% (HR=1.95, 95% CI: 1.72 to 2.20) greater risk of CVD death in Chinese communities. A low SES with the worst lifestyle was associated with a significant increase in the risk of all-cause mortality by 172% (HR=2.72, 95% CI: 2.37 to 3.12) and CVD mortality by 218% (HR=3.18, 95% CI: 2.64 to 3.83) compared with a high SES with healthy lifestyle. The joint mediating effects of lifestyles on CVD mortality accounted for 19.6% (95%CI: 14.8% to 24.2%) of the excess mortality risk for individuals with low SES, and these effects varied by genders (p for interaction=0.013) and urbanity (p for interaction=0.004). Leisure-time physical activity was the strongest mediator, followed by dietary factors. For all-cause mortality, outcomes were similar to this. Conclusions Both SES-related health inequalities and lifestyle disparities should be comprehensively considered when caring for this population, and upstream structural interventions that integrate SES and lifestyle factors and are tailored to the target population are urgently needed. Trial registration number NCT02536456.
- Open Access
Forecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort
Background Cardiovascular disease (CVD) remains a significant public health challenge in China. This study aimed to project the burden of CVD from 2020 to 2030 using a nationwide cohort and to simulate the potential impact of various control measures on morbidity and mortality. Methods An agent-based model was employed to simulate annual CVD incidence and mortality from 2021 to 2030. The effects of different prevention and treatment interventions, modelled on international strategies, were also explored. Results The study included 106 259 participants. The annual CVD incidence rate is projected to increase from 0.74% in 2021 to 0.97% by 2030, with age-standardised and sex-standardised rates rising from 0.71% to 0.96%. CVD mortality is expected to rise from 0.39% in 2021 to 0.46% in 2024, after which it will stabilise at 0.44% by 2030. Community-based interventions and improved access to inpatient care are predicted to reduce the projected burden of CVD significantly. Conclusions The incidence of CVD in China is projected to increase steadily over the next decade, while mortality will plateau after 2024. Comprehensive interventions, including community-based screenings and enhanced healthcare access, could significantly mitigate the CVD burden. Trial registration number NCT02536456.
Open AccessForecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort
Background Cardiovascular disease (CVD) remains a significant public health challenge in China. This study aimed to project the burden of CVD from 2020 to 2030 using a nationwide cohort and to simulate the potential impact of various control measures on morbidity and mortality. Methods An agent-based model was employed to simulate annual CVD incidence and mortality from 2021 to 2030. The effects of different prevention and treatment interventions, modelled on international strategies, were also explored. Results The study included 106 259 participants. The annual CVD incidence rate is projected to increase from 0.74% in 2021 to 0.97% by 2030, with age-standardised and sex-standardised rates rising from 0.71% to 0.96%. CVD mortality is expected to rise from 0.39% in 2021 to 0.46% in 2024, after which it will stabilise at 0.44% by 2030. Community-based interventions and improved access to inpatient care are predicted to reduce the projected burden of CVD significantly. Conclusions The incidence of CVD in China is projected to increase steadily over the next decade, while mortality will plateau after 2024. Comprehensive interventions, including community-based screenings and enhanced healthcare access, could significantly mitigate the CVD burden. Trial registration number NCT02536456.
- Open Access
- 17 October 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (20) , e030203T
Influence of Socioeconomic Gender Inequality on Sex Disparities in Prevention and Outcome of Cardiovascular Disease: Data From a Nationwide Population Cohort in China
Background: Knowledge gaps remain in how gender‐related socioeconomic inequality affects sex disparities in cardiovascular diseases (CVD) prevention and outcome. Methods and Results: Based on a nationwide population cohort, we enrolled 3 737 036 residents aged 35 to 75 years (2014–2021). Age‐standardized sex differences and the effect of gender‐related socioeconomic inequality (Gender Inequality Index) on sex disparities were explored in 9 CVD prevention indicators. Compared with men, women had seemingly better primary prevention (aspirin usage: relative risk [RR], 1.24 [95% CI, 1.18–1.31] and statin usage: RR, 1.48 [95% CI, 1.39–1.57]); however, women's status became insignificant or even worse when adjusted for metabolic factors. In secondary prevention, the sex disparities in usage of aspirin (RR, 0.65 [95% CI, 0.63–0.68]) and statin (RR, 0.63 [95% CI, 0.61–0.66]) were explicitly larger than disparities in usage of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (RR, 0.88 [95% CI, 0.84–0.91]) or β blockers (RR, 0.67 [95% CI, 0.63–0.71]). Nevertheless, women had better hypertension awareness (RR, 1.09 [95% CI, 1.09–1.10]), similar hypertension control (RR, 1.01 [95% CI, 1.00–1.02]), and lower CVD mortality (hazard ratio, 0.46 [95% CI, 0.45–0.47]). Heterogeneities of sex disparities existed across all subgroups. Significant correlations existed between regional Gender Inequality Index values and sex disparities in usage of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (Spearman correlation coefficient, r =−0.57, P =0.0013), hypertension control ( r =−0.62, P =0.0007), and CVD mortality ( r =0.45, P =0.014), which remained significant after adjusting for economic factors. Conclusions: Notable sex disparities remain in CVD prevention and outcomes, with large subgroup heterogeneities. Gendered socioeconomic factors could reinforce such disparities. A sex‐specific perspective factoring in socioeconomic disadvantages could facilitate more targeted prevention policy making.
- 17 October 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (20) , e030203T
Open AccessInfluence of Socioeconomic Gender Inequality on Sex Disparities in Prevention and Outcome of Cardiovascular Disease: Data From a Nationwide Population Cohort in China
Background: Knowledge gaps remain in how gender‐related socioeconomic inequality affects sex disparities in cardiovascular diseases (CVD) prevention and outcome. Methods and Results: Based on a nationwide population cohort, we enrolled 3 737 036 residents aged 35 to 75 years (2014–2021). Age‐standardized sex differences and the effect of gender‐related socioeconomic inequality (Gender Inequality Index) on sex disparities were explored in 9 CVD prevention indicators. Compared with men, women had seemingly better primary prevention (aspirin usage: relative risk [RR], 1.24 [95% CI, 1.18–1.31] and statin usage: RR, 1.48 [95% CI, 1.39–1.57]); however, women's status became insignificant or even worse when adjusted for metabolic factors. In secondary prevention, the sex disparities in usage of aspirin (RR, 0.65 [95% CI, 0.63–0.68]) and statin (RR, 0.63 [95% CI, 0.61–0.66]) were explicitly larger than disparities in usage of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (RR, 0.88 [95% CI, 0.84–0.91]) or β blockers (RR, 0.67 [95% CI, 0.63–0.71]). Nevertheless, women had better hypertension awareness (RR, 1.09 [95% CI, 1.09–1.10]), similar hypertension control (RR, 1.01 [95% CI, 1.00–1.02]), and lower CVD mortality (hazard ratio, 0.46 [95% CI, 0.45–0.47]). Heterogeneities of sex disparities existed across all subgroups. Significant correlations existed between regional Gender Inequality Index values and sex disparities in usage of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (Spearman correlation coefficient, r =−0.57, P =0.0013), hypertension control ( r =−0.62, P =0.0007), and CVD mortality ( r =0.45, P =0.014), which remained significant after adjusting for economic factors. Conclusions: Notable sex disparities remain in CVD prevention and outcomes, with large subgroup heterogeneities. Gendered socioeconomic factors could reinforce such disparities. A sex‐specific perspective factoring in socioeconomic disadvantages could facilitate more targeted prevention policy making.